Alport综合征诊断、管理与治疗:2024年ERKNet、ERA和ESPN指南
该指南由ERKNet、ERA和ESPN联合制定,基于21个PICO问题的系统文献综述,为COL4A3/4/5基因致病变异个体的诊断与管理提供推荐。关键推荐包括:对持续性血尿等患者行COL4A3/4/5联合基因检测,早期使用RAS阻断剂作为标准治疗,成人蛋白尿合并CKD可加用SGLT2抑制剂,杂合变异亲属应仅作为活体肾移植的最后选择。
要点
- 持续性血尿、蛋白尿、不明原因肾衰竭等患者应行COL4A3/4/5基因联合检测。
- 早期RAS阻断剂是标准治疗;成人蛋白尿合并CKD可加用SGLT2抑制剂。
- 杂合COL4A3/4/5变异亲属应仅作为活体肾移植的最后选择。
核心结论
- 指南为COL4A3/4/5基因致病变异个体的诊断与管理提供循证推荐。
研究设计与样本
- 由ERKNet、ERA和ESPN联合组建多学科专家组,针对21个临床相关PICO问题进行系统文献综述。
- 专家在共识会议上形成推荐并正式分级,纳入患者代表和全球多地区肾脏病专家投票。
主要发现
- COL4A3/4/5基因肾小球病是第二常见遗传性肾病,表现为持续性血尿进展至肾替代治疗,常伴感音神经性耳聋,偶有眼部异常。
- 该病表型异质、遗传模式多样、变异表现度和外显率不一,预后与进展因素不完善且临床试验有限。
关键数值与推荐
- 对持续性血尿、蛋白尿、不明原因肾衰竭、不明原因局灶节段性硬化及可能的囊性肾病,初始评估应行COL4A3/4/5基因联合分析。
- 早期RAS阻断是标准治疗;成人蛋白尿合并CKD可加用SGLT2抑制剂。
- 杂合COL4A3/4/5变异亲属应仅作为活体肾移植的最后选择。
临床怎么用
- 对疑似患者应尽早进行COL4A3/4/5基因检测以明确诊断。
- 确诊后早期启动RAS阻断剂,成人蛋白尿合并CKD可考虑加用SGLT2抑制剂。
- 评估活体肾移植供者时,杂合COL4A3/4/5变异亲属应作为最后选择。
局限性
- 临床试验尤其儿童领域 scarce and limited,预后与进展因素不完善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glomerular nephropathy resulting from the genetic defects in COL4A3/4/5 genes including the classical Alport syndrome is the second most common hereditary kidney disease characterized by persistent haematuria progressing to the need for kidney replacement therapy, frequently associated with sensorineural deafness, and occasionally with ocular anomalies. Diagnosis and management of COL4A3/4/5 glomerulopathy is a great challenge due to its phenotypic heterogeneity, multiple modes of inheritance, variable expressivity, and disease penetrance of individual variants as well as imperfect prognostic and progression factors and scarce and limited clinical trials, especially in children. As a joint initiative of the European Rare Kidney disease reference Network (ERKNet), European Renal Association (ERA Genes&Kidney), and European Society for Paediatric Nephrology (ESPN) Inherited renal disorders working group, a team of experts including adult and paediatric nephrologists, kidney geneticists, audiologists, ophthalmologists, and a kidney pathologist were selected to perform a systematic literature review on 21 clinically relevant PICO (Patient or Population covered, Intervention, Comparator, Outcome) questions. The experts formulated recommendations and formally graded them at a consensus meeting with input from patient representatives and a voting panel of nephrologists representing all regions of the world. Genetic diagnostics comprising joint analysis of COL4A3/4/5 genes is already the key diagnostic test during the initial evaluation of an individual presenting with persistent haematuria, proteinuria, kidney failure of unknown origin, focal segmental sclerosis of unknown origin, and possibly cystic kidney disease. Early renin-angiotensin system blockade is the standard of care therapy; sodium-glucose cotransporter-2 inhibitors may be added in adults with proteinuria and chronic kidney disease. Relatives with heterozygous COL4A3/4/5 variants should only be considered as the last possible resource for living kidney donation. This guideline provides guidance for the diagnosis and management of individuals with pathogenic variants in COL4A3/4/5 genes.
引用
- Torra R, Lipska-Zietkiewicz B, Acke F, et al. Diagnosis, management and treatment of the Alport syndrome - 2024 guideline on behalf of ERKNet, ERA and ESPN. Nephrol Dial Transplant. 2025. PMID: 39673454. doi:10.1093/ndt/gfae265
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。